glp-1 hormones Glucagon-like peptide-1 Glucagon-like peptide (GLP)-1 and GLP-2

Dula (50, 100, and 150 g/kg) substantially reduced the colon's weight, the ratio of weight to length, serum CRP, and LDH levels, boosted histopathological alterations and displayed anti-colitis and anti-inflammatory actions

Transdermal delivery systems could potentially offer advantages over subcutaneous injections, including improved patient acceptability and reduced injection-site reactions

GLP-1 agonists are medicines that work like the GLP-1 hormone produced in your body, helping to regulate blood sugar levels in several ways, including: Slowing digestion after a meal (some of these medications more than others) Reducing glucagon from the pancreas (which signals your cells to release stored glucose and increase blood glucose levels) Increasing insulin release from the pancreas Promoting the feeling of being full after eating These medicines help people with type 2 diabetes manage their blood sugar levels

doi: 10.2337/db18-0155 77 Gonzalez-PerezASchliengerRGRodrguezLA

Critics of GLP-1 therapies often portray those who use these medications as opting for an easy way out to achieve thinness, perpetuating longstanding biases like those historically associated with bariatric surgery (Heitmann, 2025)

Research suggests that continued metformin use and structured exercise programs can help reduce weight regain